On the recordDecember 7, 2021
I am concerned about the drug pricing protocols in the Build Back Better Act, and they would have the opposite effect limiting research and hampering innovation, in my view.
Source
congress.govEditor's note · Context
Bucshon criticizes the drug pricing measures in the Build Back Better Act for hindering innovation.
Share & report
More from Larry Bucshon
Sep 24, 2019
The U.S. Federal Government, potentially, in the negotiations could make policy decisions that are essentially medical decisions on who gets access and who doesn't based on cost.
Sep 18, 2019
I would implore us to bring bipartisan bills passed unanimously out of this committee to bring down drug prices to the floor for a vote.
Mar 2, 2020
In my opinion, that is exactly what H.R. 2482, the Mainstream Addiction Treatment Act does. It removes education requirements and limits making it easier to prescribe a medication known to be highly diverted and misused.
Oct 22, 2019
First off, I want to thank you for your recent proposal to reform Stark Law.
Other voices in this conversation
